Valuation: Viyash Scientific Limited

Market Cap 10TCr 105.24Cr 94Cr 87Cr 80Cr 150.03Cr 151.42Cr 1.06TCr 409.27Cr 5.17TCr 395.13Cr 386.55Cr 17TCr P/E 2027 *
33.1x
P/E 2028 * 20x
Enterprise Value 10TCr 105.24Cr 94Cr 87Cr 80Cr 150.03Cr 151.42Cr 1.06TCr 409.27Cr 5.17TCr 395.13Cr 386.55Cr 17TCr EV / Sales 2027 *
2.59x
EV / Sales 2028 * 2.26x
Free-Float
44.39%
Yield 2027 *
-
Yield 2028 * -
1 day-1.72%
1 week-5.17%
Current month-1.72%
1 month-10.55%
3 months-20.71%
6 months+20.82%
Current year+11.36%
1 week 226.3
Extreme 226.3
246
1 month 226.3
Extreme 226.3
268.4
Current year 178.4
Extreme 178.4
297.9
1 year 178.4
Extreme 178.4
297.9
3 years 90.61
Extreme 90.61
297.9
5 years 61.8
Extreme 61.8
297.9
10 years 42.45
Extreme 42.45
336.4
Manager TitleAgeSince
Chief Executive Officer 62 16/12/2025
Director of Finance/CFO - 01/01/2026
Chief Tech/Sci/R&D Officer - 05/02/2026
Director TitleAgeSince
Chairman 78 25/08/2025
Director/Board Member 67 25/08/2020
Director/Board Member 57 11/04/2022
Change 5-day change 1-year change 3-year change Capi.($)
-1.72%-5.17%+19.12%+150.08% 105.24Cr
-0.61%-3.43%+39.40%+112.31% 1,01900Cr
-1.02%-5.60%+37.67%+65.02% 62TCr
+1.11%-0.58%+11.10%+77.28% 46TCr
+0.34%-3.01%+61.21%+40.71% 36TCr
-0.95%-4.05%+21.60%+39.37% 33TCr
-1.46%-2.89%+11.84%+24.60% 27TCr
-1.35%-5.43%-4.69%+8.40% 24TCr
-1.04%-2.79%+35.52%+51.34% 22TCr
-1.87%-4.10%+30.92%+95.33% 18TCr
Average -0.38%-3.63%+26.37%+66.44% 36.98TCr
Weighted average by Cap. +0.42%-3.33%+30.51%+68.98%

Financials

2027 *2028 *
Net sales 3.9TCr 41Cr 36Cr 34Cr 31Cr 58Cr 58Cr 407.07Cr 157.74Cr 1.99TCr 152.29Cr 148.99Cr 6.4TCr 4.47TCr 46Cr 41Cr 39Cr 35Cr 66Cr 67Cr 466.47Cr 180.76Cr 2.28TCr 174.51Cr 170.73Cr 7.33TCr
Net income 343.83Cr 3.58Cr 3.18Cr 2.97Cr 2.7Cr 5.1Cr 5.15Cr 36Cr 14Cr 175.77Cr 13Cr 13Cr 564.12Cr 539.52Cr 5.61Cr 4.99Cr 4.65Cr 4.24Cr 8Cr 8.07Cr 56Cr 22Cr 275.81Cr 21Cr 21Cr 885.18Cr
Net Debt - -
Logo Viyash Scientific Limited
Viyash Scientific Limited, formerly SeQuent Scientific Limited, is an India-based integrated pharmaceutical company with a global footprint, operating in the domains of animal health (active pharmaceutical ingredients (APIs), and finished dosage formulations) and analytical services. The Company has eight manufacturing facilities, based in India, Turkey, Brazil, Spain and Germany. It is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It specializes in analytical and bioanalytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It offers analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer-developed methods or in-house method development.
Employees
2,900
Date Price Change Volume
01/26/01 ₹231.80 -1.72% 1,96,550
30/26/30 ₹235.85 -0.92% 43,210
29/26/29 ₹238.05 -1.14% 1,67,376
28/26/28 ₹240.80 -1.49% 92,155
25/26/25 ₹244.45 -0.65% 59,212
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
231.80INR
Average target price
322.25INR
Spread / Average Target
+39.02%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VIYASH Stock